154235-83-3

154235-83-3 structure

Name: Ampalex
Chemical Name: Piperidin-1-yl(quinoxalin-6-yl)methanone
CAS Number: 154235-83-3
Molecular Formula: C₁₄H₁₅N₃O
Molecular Weight: 241.288
Catalog: Signaling Pathways Membrane Transporter/Ion Channel iGluR
Create Date: 2018-06-29 18:22:04
Modify Date: 2024-01-02 09:46:30
Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). IC50 value: Target: AMPA receptorAmpalex ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Researches suggest that AMPA receptors may be potential pharmaceutical targets for the treatment of neurodegenerative diseases, and highlights AMPAkines, in particular, as possible therapeutic agents.

Name	Piperidin-1-yl(quinoxalin-6-yl)methanone
Synonyms	Methanone, 1-piperidinyl-6-quinoxalinyl- piperidin-1-yl(quinoxalin-6-yl)methanone 1-Piperidinyl(6-quinoxalinyl)methanone 1-(quinoxalin-6-ylcarbonyl)piperidine Ampalex BDP-12

Description	Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). IC50 value: Target: AMPA receptorAmpalex ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Researches suggest that AMPA receptors may be potential pharmaceutical targets for the treatment of neurodegenerative diseases, and highlights AMPAkines, in particular, as possible therapeutic agents.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> iGluR Signaling Pathways >> Neuronal Signaling >> iGluR Research Areas >> Neurological Disease
References	[1]. Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 [2]. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61. [3]. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465-72. [4]. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20. [5]. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.

Density	1.2±0.1 g/cm3
Boiling Point	433.1±25.0 °C at 760 mmHg
Melting Point	88-90ºC
Molecular Formula	C₁₄H₁₅N₃O
Molecular Weight	241.288
Flash Point	215.8±23.2 °C
Exact Mass	241.121506
PSA	46.09000
LogP	0.57
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.640
Storage condition	2~8℃

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Hazard Codes	Xi
RIDADR	NONH for all modes of transport
RTECS	TM2785170
HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4